Home/Filings/4/0001735276-24-000022
4//SEC Filing

SHARP PHILLIP A 4

Accession 0001735276-24-000022

CIK 0001178670other

Filed

Feb 29, 7:00 PM ET

Accepted

Mar 1, 4:12 PM ET

Size

19.1 KB

Accession

0001735276-24-000022

Insider Transaction Report

Form 4
Period: 2024-02-29
Transactions
  • Sale

    Common Stock

    2024-02-29$154.07/sh101$15,561516 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2024-02-2930,0000 total
    Exercise: $59.25From: 2015-06-05Exp: 2024-06-04Common Stock (30,000 underlying)
  • Sale

    Common Stock

    2024-02-29$156.54/sh516$80,7750 total
  • Exercise/Conversion

    Common Stock

    2024-02-29$59.25/sh+30,000$1,777,50030,000 total
  • Sale

    Common Stock

    2024-02-29$153.62/sh1,906$292,800617 total
  • Sale

    Common Stock

    2024-02-29$150.60/sh13,005$1,958,55316,995 total
  • Sale

    Common Stock

    2024-02-29$151.43/sh13,557$2,052,9373,438 total
  • Sale

    Common Stock

    2024-02-29$152.40/sh915$139,4462,523 total
Holdings
  • Common Stock

    (indirect: By Trust)
    266,899
Footnotes (8)
  • [F1]The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2023. The 30,000 options exercised and sold by the reporting person were due to expire on June 4, 2024.
  • [F2]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $150.00 to $151.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F3]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $151.01 to $151.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F4]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $152.02 to $152.91. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F5]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $153.04 to $154.03. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F6]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $154.06 to $154.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F7]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $156.15 to $156.98. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F8]Includes shares held by the Phillip A. Sharp Revocable Trust, of which the reporting person and his spouse are co-trustees. Also includes shares held in trust for the benefit of the reporting persons children, of which the reporting persons children and spouse are the trustees.

Issuer

ALNYLAM PHARMACEUTICALS, INC.

CIK 0001178670

Entity typeother
IncorporatedMA

Related Parties

1
  • filerCIK 0001226295

Filing Metadata

Form type
4
Filed
Feb 29, 7:00 PM ET
Accepted
Mar 1, 4:12 PM ET
Size
19.1 KB